Published in Nucleic Acids Res on June 01, 2003
Structural basis for overhang-specific small interfering RNA recognition by the PAZ domain. Nature (2004) 7.63
RISC is a 5' phosphomonoester-producing RNA endonuclease. Genes Dev (2004) 4.73
Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA (2006) 4.72
Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol (2009) 3.78
RNA interference in the clinic: challenges and future directions. Nat Rev Cancer (2010) 3.43
Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther (2008) 2.79
In vivo activity of nuclease-resistant siRNAs. RNA (2004) 2.33
Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res (2005) 2.20
Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest (2009) 2.13
Transcription factor Erg regulates angiogenesis and endothelial apoptosis through VE-cadherin. Blood (2008) 2.00
siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J Am Soc Nephrol (2009) 1.86
A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res (2009) 1.84
Chemical modification: the key to clinical application of RNA interference? J Clin Invest (2007) 1.81
RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol (2010) 1.80
Progress toward in vivo use of siRNAs-II. Mol Ther (2011) 1.60
Progress in microRNA delivery. J Control Release (2013) 1.58
Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA (2007) 1.46
MysiRNA-designer: a workflow for efficient siRNA design. PLoS One (2011) 1.45
Competition for RISC binding predicts in vitro potency of siRNA. Nucleic Acids Res (2006) 1.44
MicroRNA: An emerging therapeutic target and intervention tool. Int J Mol Sci (2008) 1.41
In situ fluorescence analysis demonstrates active siRNA exclusion from the nucleus by Exportin 5. Nucleic Acids Res (2006) 1.39
Small interfering RNAs containing full 2'-O-methylribonucleotide-modified sense strands display Argonaute2/eIF2C2-dependent activity. RNA (2005) 1.38
Light-dependent RNA interference with nucleobase-caged siRNAs. RNA (2007) 1.31
RNAi mechanisms and applications. Biotechniques (2008) 1.30
Effect of asymmetric terminal structures of short RNA duplexes on the RNA interference activity and strand selection. Nucleic Acids Res (2008) 1.21
Fabrication of stable and RNase-resistant RNA nanoparticles active in gearing the nanomotors for viral DNA packaging. ACS Nano (2010) 1.21
Novel RNA-based strategies for therapeutic gene silencing. Mol Ther (2010) 1.20
Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs. Oligonucleotides (2008) 1.17
Effects of cholesterol-tagged small interfering RNAs targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in a mouse model of type 1 diabetes. Am J Physiol Renal Physiol (2008) 1.16
Effect of base modifications on structure, thermodynamic stability, and gene silencing activity of short interfering RNA. RNA (2007) 1.16
Research progress on siRNA delivery with nonviral carriers. Int J Nanomedicine (2011) 1.13
RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res (2004) 1.11
Crystal structure, stability and in vitro RNAi activity of oligoribonucleotides containing the ribo-difluorotoluyl nucleotide: insights into substrate requirements by the human RISC Ago2 enzyme. Nucleic Acids Res (2007) 1.11
Relative gene-silencing efficiencies of small interfering RNAs targeting sense and antisense transcripts from the same genetic locus. Nucleic Acids Res (2004) 1.10
MALDI-TOF mass spectral analysis of siRNA degradation in serum confirms an RNAse A-like activity. Mol Biosyst (2006) 1.10
Defining features and exploring chemical modifications to manipulate RNAa activity. Curr Pharm Biotechnol (2010) 1.09
Stability study of unmodified siRNA and relevance to clinical use. Oligonucleotides (2008) 1.08
Inhibition of MDR1 expression with altritol-modified siRNAs. Nucleic Acids Res (2007) 1.06
RNAi for treating hepatitis B viral infection. Pharm Res (2007) 1.05
Controlling activation of the RNA-dependent protein kinase by siRNAs using site-specific chemical modification. Nucleic Acids Res (2006) 1.04
Light-activated RNA interference using double-stranded siRNA precursors modified using a remarkable regiospecificity of diazo-based photolabile groups. Nucleic Acids Res (2009) 1.04
Quantitative evaluation of siRNA delivery in vivo. RNA (2010) 1.03
The emerging role of miRNAs in inflammatory bowel disease: a review. Therap Adv Gastroenterol (2015) 1.03
Effects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs. RNA (2009) 1.02
Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut (2005) 1.02
Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev (2015) 1.01
Concepts in in vivo siRNA delivery for cancer therapy. J Cell Physiol (2009) 0.98
Sequence determinants of innate immune activation by short interfering RNAs. BMC Immunol (2009) 0.98
Logic integration of mRNA signals by an RNAi-based molecular computer. Nucleic Acids Res (2010) 0.98
Chemical modification resolves the asymmetry of siRNA strand degradation in human blood serum. RNA (2007) 0.97
mRNA knockdown by single strand RNA is improved by chemical modifications. Nucleic Acids Res (2012) 0.97
Effect of chemical modifications on modulation of gene expression by duplex antigene RNAs that are complementary to non-coding transcripts at gene promoters. Nucleic Acids Res (2010) 0.97
Regulation and functional role of the Runt-related transcription factor-2 in pancreatic cancer. Br J Cancer (2007) 0.96
Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering. Front Genet (2012) 0.95
microRNA therapies in cancer. Mol Cell Ther (2014) 0.95
Efficient RNA interference depends on global context of the target sequence: quantitative analysis of silencing efficiency using Eulerian graph representation of siRNA. Nucleic Acids Res (2004) 0.94
MicroRNAs in fibrosis: opportunities and challenges. Arthritis Res Ther (2016) 0.93
Duplex end breathing determines serum stability and intracellular potency of siRNA-Au NPs. Mol Pharm (2011) 0.93
Degradation of nuclease-stabilized RNA oligonucleotides in Mycoplasma-contaminated cell culture media. Nucleic Acid Ther (2012) 0.92
Toll-like receptor (TLR) 3 immune modulation by unformulated small interfering RNA or DNA and the role of CD14 (in TLR-mediated effects). Immunology (2012) 0.92
Functionalized gold nanoparticles for the binding, stabilization, and delivery of therapeutic DNA, RNA, and other biological macromolecules. Nanotechnol Sci Appl (2010) 0.90
Efficient delivery of small interfering RNA for inhibition of IL-12p40 expression in vivo. J Inflamm (Lond) (2004) 0.90
miRNA-Based Therapeutic Strategies. Curr Anesthesiol Rep (2012) 0.89
RNA interference in mammalia cells by RNA-3'-PNA chimeras. Int J Mol Sci (2008) 0.89
REDD2-mediated inhibition of mTOR promotes dendrite retraction induced by axonal injury. Cell Death Differ (2014) 0.88
siRNA targeting Hes5 augments hair cell regeneration in aminoglycoside-damaged mouse utricle. Mol Ther (2013) 0.88
Therapeutic evaluation of microRNAs by molecular imaging. Theranostics (2013) 0.88
Structural diversity repertoire of gene silencing small interfering RNAs. Nucleic Acid Ther (2011) 0.87
Advances in Systemic siRNA Delivery. Drugs Future (2009) 0.87
Effects of the knockdown of hypoxia inducible factor-1α expression by adenovirus-mediated shRNA on angiogenesis and tumor growth in hepatocellular carcinoma cell lines. Korean J Hepatol (2010) 0.86
RNA interference and antiviral therapy. World J Gastroenterol (2007) 0.86
Effect of lyophilization and freeze-thawing on the stability of siRNA-liposome complexes. AAPS PharmSciTech (2007) 0.85
Biological effects of hexitol and altritol-modified siRNAs targeting B-Raf. Eur J Pharmacol (2009) 0.85
siRNA-optimized Modifications for Enhanced In Vivo Activity. Mol Ther Nucleic Acids (2012) 0.85
MicroRNA 199b-5p delivery through stable nucleic acid lipid particles (SNALPs) in tumorigenic cell lines. Naunyn Schmiedebergs Arch Pharmacol (2013) 0.85
8-Oxoguanosine switches modulate the activity of alkylated siRNAs by controlling steric effects in the major versus minor grooves. J Am Chem Soc (2011) 0.84
siRNA-like double-stranded RNAs are specifically protected against degradation in human cell extract. PLoS One (2011) 0.84
RNA interference for improving the outcome of islet transplantation. Adv Drug Deliv Rev (2010) 0.84
Delivery of therapeutic siRNA to the lung endothelium via novel Lipoplex formulation DACC. Mol Ther (2014) 0.84
Personalized cancer approach: using RNA interference technology. World J Surg (2011) 0.83
Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration. Nucleic Acid Ther (2012) 0.83
Bioconjugates for targeted delivery of therapeutic oligonucleotides. Adv Drug Deliv Rev (2015) 0.83
Human Papillomavirus E6/E7-Specific siRNA Potentiates the Effect of Radiotherapy for Cervical Cancer in Vitro and in Vivo. Int J Mol Sci (2015) 0.82
Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden. Nanomedicine (2015) 0.82
Fluorescence cross-correlation spectroscopy reveals mechanistic insights into the effect of 2'-O-methyl modified siRNAs in living cells. Biophys J (2011) 0.82
MicroRNAs in heart failure: Small molecules with major impact. Glob Cardiol Sci Pract (2014) 0.82
Superparamagnetic iron oxide nanoparticles mediated (131)I-hVEGF siRNA inhibits hepatocellular carcinoma tumor growth in nude mice. BMC Cancer (2014) 0.82
High-density lipoproteins for the systemic delivery of short interfering RNA. Expert Opin Drug Deliv (2013) 0.82
Intracellular stability of 2'-OMe-4'-thioribonucleoside modified siRNA leads to long-term RNAi effect. Nucleic Acids Res (2012) 0.81
Epigenetic manipulation of gene expression: a toolkit for cell biologists. J Cell Biol (2005) 0.81
Targeted delivery of siRNA. J Biomed Biotechnol (2006) 0.81
Probing the inherent stability of siRNA immobilized on nanoparticle constructs. Proc Natl Acad Sci U S A (2014) 0.81
Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy. Int J Nanomedicine (2011) 0.81
Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells. Oncoimmunology (2015) 0.81
Gene control of tyrosine kinase TIE2 and vascular manifestations of infections. Proc Natl Acad Sci U S A (2016) 0.80
Synthesis of ¹⁸O-labeled RNA for application to kinetic studies and imaging. Nucleic Acids Res (2013) 0.80
In vivo screening of modified siRNAs for non-specific antiviral effect in a small fish model: number and localization in the strands are important. Nucleic Acids Res (2012) 0.80
Positive feedback loop of hepatoma-derived growth factor and β-catenin promotes carcinogenesis of colorectal cancer. Oncotarget (2015) 0.80
Sniffing for gene-silencing efficiency of siRNAs in HeLa cells in comparison with that in HEK293T cells: correlation between knockdown efficiency and sustainability of sirnas revealed by FRET-based probing. Nucleic Acid Ther (2013) 0.79
Short-interference RNAs: becoming medicines. EXCLI J (2015) 0.78
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 72.56
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 57.23
Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature (2001) 38.75
RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev (2001) 26.16
An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature (2000) 23.17
RNA interference. Nature (2002) 22.28
Regulation of heterochromatic silencing and histone H3 lysine-9 methylation by RNAi. Science (2002) 17.04
Argonaute2, a link between genetic and biochemical analyses of RNAi. Science (2001) 15.32
Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell (2002) 14.37
Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J (2001) 12.88
ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell (2001) 10.20
Establishment and maintenance of a heterochromatin domain. Science (2002) 9.34
Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. Mol Cell (2002) 6.43
Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor. Nucleic Acids Res (2002) 5.93
Stable suppression of gene expression by RNAi in mammalian cells. Proc Natl Acad Sci U S A (2002) 5.05
Specific interference with gene expression induced by long, double-stranded RNA in mouse embryonal teratocarcinoma cell lines. Proc Natl Acad Sci U S A (2001) 4.79
Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res (2003) 3.85
RNAi in human cells: basic structural and functional features of small interfering RNA. Mol Cell (2002) 3.81
Expanding small RNA interference. Nat Biotechnol (2002) 3.41
PKR--a protein kinase regulated by double-stranded RNA. Int J Biochem Cell Biol (1997) 2.34
Short 5'-phosphorylated double-stranded RNAs induce RNA interference in Drosophila. Curr Biol (2001) 1.91
The interaction of small domains between the subunits of phosphatidylinositol 3-kinase determines enzyme activity. Mol Cell Biol (1994) 1.91
Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. J Biol Chem (1995) 1.54
Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA. Nucleic Acids Res (2003) 1.47
Small interfering RNAs: a revolutionary tool for the analysis of gene function and gene therapy. Mol Interv (2002) 1.36
Stabilizing effects of the RNA 2'-substituent: crystal structure of an oligodeoxynucleotide duplex containing 2'-O-methylated adenosines. Chem Biol (1994) 1.32
Metabolism of antisense oligonucleotides in rat liver homogenates. J Pharmacol Exp Ther (2000) 1.24
GeneBlocs are powerful tools to study and delineate signal transduction processes that regulate cell growth and transformation. Antisense Nucleic Acid Drug Dev (2002) 0.99
Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol (2013) 2.33
Lung-targeted RNA interference against angiopoietin-2 ameliorates multiple organ dysfunction and death in sepsis. Crit Care Med (2014) 1.83
REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase. Oncogene (2005) 1.49
Functional studies of the PI(3)-kinase signalling pathway employing synthetic and expressed siRNA. Nucleic Acids Res (2003) 1.47
Differential regulation of TGF-beta signaling through Smad2, Smad3 and Smad4. Oncogene (2003) 1.46
The mitochondrial protein MTP18 contributes to mitochondrial fission in mammalian cells. J Cell Sci (2005) 1.44
Inducible shRNA expression for application in a prostate cancer mouse model. Nucleic Acids Res (2003) 1.35
Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res (2008) 1.34
TRB3 is a PI 3-kinase dependent indicator for nutrient starvation. Cell Signal (2005) 1.20
Peroxiredoxin 6 is required for blood vessel integrity in wounded skin. J Cell Biol (2007) 1.12
Loss of Drp1 function alters OPA1 processing and changes mitochondrial membrane organization. Exp Cell Res (2009) 1.12
Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90. Chem Biol (2010) 1.09
PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase. EMBO J (2004) 1.06
Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor. J Biol Chem (2010) 1.03
Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int J Clin Pharmacol Ther (2012) 1.02
Knockdown of MTP18, a novel phosphatidylinositol 3-kinase-dependent protein, affects mitochondrial morphology and induces apoptosis. J Biol Chem (2004) 1.00
GeneBlocs are powerful tools to study and delineate signal transduction processes that regulate cell growth and transformation. Antisense Nucleic Acid Drug Dev (2002) 0.99
Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models. Clin Cancer Res (2010) 0.94
The interaction of PKN3 with RhoC promotes malignant growth. Mol Oncol (2011) 0.93
Regulation of epidermal homeostasis and repair by phosphoinositide 3-kinase. J Cell Sci (2006) 0.93
Intracellular localization of lipoplexed siRNA in vascular endothelial cells of different mouse tissues. Microvasc Res (2008) 0.87
Smad3 is a key nonredundant mediator of transforming growth factor beta signaling in Nme mouse mammary epithelial cells. Mol Cancer Res (2009) 0.87
Sequencing of single and double stranded RNA oligonucleotides by acid hydrolysis and MALDI mass spectrometry. Anal Chem (2009) 0.86
Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice. Clin Rheumatol (2015) 0.81
Kinetic mechanism and catalysis of a native-state prolyl isomerization reaction. J Mol Biol (2003) 0.81
RNAi-mediated suppression of constitutive pulmonary gene expression by small interfering RNA in mice. Pulm Pharmacol Ther (2010) 0.81
Enzyme Kinetics and Distinct Modulation of the Protein Kinase N Family of Kinases by Lipid Activators and Small Molecule Inhibitors. Biosci Rep (2014) 0.81
Effect of proline to alanine mutation on the thermal stability of the all-beta-sheet protein tendamistat. Biochim Biophys Acta (2003) 0.80
Unravelling novel intracellular pathways in cell-based assays. Drug Discov Today (2002) 0.78
Detection and relative quantification of siRNA double strands by MALDI mass spectrometry. Anal Chem (2008) 0.77
Depletion of protein kinase N3 (PKN3) impairs actin and adherens junctions dynamics and attenuates endothelial cell activation. Eur J Cell Biol (2012) 0.77
Oligonucleotides suppress PKB/Akt and act as superinductors of apoptosis in human keratinocytes. Nucleic Acids Res (2009) 0.75